Lite Strategy reported $16.0 million in net income for its fiscal 2027 first quarter, with a 60% increase in $LTC boosting the value of its treasury holdings. In results released on November 10, 2026, for the quarter ended September 30, 2026, the company also reported a lower share count, reduced operating costs and no debt.
Key takeaways
- Quarterly buybacks reduced Lite Strategy’s share count by 6.8%.
- At quarter-end, the company held 751,798 $LTC, valued at $50.5 million.
- Cash used in operations was down 52% from the same quarter a year earlier.
- The company is investing in LitVM and pursuing partnerships and acquisitions focused on Litecoin.
Litecoin gains and treasury income underpin Lite Strategy’s results
Lite Strategy said most of its quarterly profit came from revaluing its $LTC holdings after Litecoin’s 60% appreciation. The quarter marked the start of the second fiscal year of its Litecoin treasury strategy, adopted in 2025.
The Nasdaq-listed company, which trades as LITS, repurchased approximately 2.2 million shares at an average of $1.08 during the quarter. It said the purchases were made at a discount to net asset value in the low 20% range. By September 30, 2026, repurchases since the program began amounted to approximately 18% of shares.
Buybacks continued in October 2026, when the company purchased another 825,181 shares at a weighted-average price of $1.27. As of October 30, 2026, shares outstanding totaled 29,884,653.
The covered call program generated approximately $130,000 in quarterly premiums, bringing cumulative proceeds to about $1.1 million in slightly more than a year. Lite Strategy said its repurchases were funded entirely by active treasury operations and that it had no debt on its balance sheet.
General and administrative expenses fell 24% to $2.4 million. Net cash used in operations declined 52% to $2.2 million compared with the corresponding quarter a year earlier.
As of September 30, 2026, the company held 751,798 $LTC worth $50.5 million, including 64,700 $LTC pledged as collateral for covered call options. It also had $4.3 million in cash and cash equivalents and $46.2 million in unrestricted digital assets. Total assets were $58.4 million, while liabilities totaled $1.7 million.
Regulatory classification and LitVM investment
Lite Strategy’s update referred to the SEC’s March 2026 Digital Asset Interpretation, which classified Litecoin as a digital commodity rather than a security. The company said the CFTC confirmed it would continue to regulate $LTC on that basis.
In August 2026, the SEC later proposed Regulation Crypto Assets, with public comments closing on October 20, 2026. Lite Strategy said these developments gave corporate treasuries, asset managers and other institutions a clearer basis for evaluating exposure to $LTC.
In addition to holding the token, the company is the lead institutional investor in LitVM—a zero-knowledge Layer-2 platform developing smart-contract functionality for Litecoin. LitVM is progressing toward its mainnet launch.
The platform is designed to support decentralized finance, stablecoin issuance and tokenized assets, with $LTC as its native token. Litecoin creator and Lite Strategy board member Charlie Lee said smart contracts and regulatory recognition are helping the network expand beyond payments.
Fiscal 2027 priorities and pharmaceutical assets
Lite Strategy’s priorities include increasing the amount of $LTC backing each common share through selective acquisitions, strategic partnerships and disciplined capital deployment. Management also intends to expand its institutional investor base during fiscal 2027.
CEO and CFO Jay File said the company evaluates capital allocation decisions based on their expected contribution to value per share. Alongside its Litecoin results, Lite Strategy described plans to expand operating activity across the ecosystem, supported by established custody arrangements, internal controls, and compliance with SEC and Nasdaq requirements.
The company is also continuing preclinical work on voruciclib, an oral CDK9 inhibitor, for non-oncology uses. Preliminary ex vivo studies found changes in immune cell subsets that supported further development in animal models. Lite Strategy is considering licensing or sale opportunities for both voruciclib and zandelisib as potential sources of non-dilutive capital.
Article produced with the assistance of artificial intelligence and reviewed by the editorial team.
Source: en.cryptonomist.ch. Adapted by NBTC.
Add A Comment
Comments are closed.